V2a Interneuron Differentiation via Signaling Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The lack of a robust source of human V2a interneurons limits molecular profiling and therapeutic potential for central nervous system injuries, as current methods are inefficient in generating these neurons from human pluripotent stem cells.
Innovation Solution
A method involving culturing human pluripotent stem cells in a neural induction medium with retinoic acid, sonic hedgehog, and Notch signaling pathway modulators to differentiate into CHX10+ V2a interneurons, which are then matured in vitro or in vivo to acquire functional properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional differentiation methods are used, then general neuronal populations are generated, but V2a interneuron yield and purity are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying signaling pathway activators and inhibitors in the differentiation medium. Specifically, it optimizes the concentration and timing of retinoic acid (RA) signaling activators, Shh signaling activators, and Notch signaling inhibitors to achieve high-yield V2a interneuron differentiation. This involves adjusting chemical parameters such as RA concentration (e.g., 100 nM), Shh agonist concentration (e.g., 1 μM), and Notch inhibitor concentration (e.g., 10 μM DAPT) to control cell fate decisions and maximize V2a interneuron production while maintaining purity
Solution Approach 2:
The patent employs preliminary action by pre-determining the sequential application of signaling modulators during early differentiation stages. Before committing to V2a interneuron fate, the method pre-establishes appropriate signaling conditions: first activating RA and Shh pathways, then introducing Notch inhibition at specific time points (e.g., day 3-5 of differentiation). This preliminary control of signaling parameters ensures high purity V2a interneuron generation by preventing off-target differentiation before it occurs
2Productivity
If signaling pathway modulators are added to neural induction medium, then V2a interneuron differentiation is enhanced, but medium complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the differentiation process into distinct temporal phases, each with specific signaling modulator combinations. Rather than using all modulators simultaneously throughout culture, the method segments the protocol into: (1) early neural induction phase with RA and Shh activators only, (2) intermediate phase adding Notch inhibitors, and (3) late maturation phase with adjusted concentrations. This temporal segmentation reduces medium complexity at any given time while maintaining high V2a interneuron generation efficiency
Solution Approach 2:
The patent implements periodic action by cycling through different signaling modulator regimens at specific intervals during differentiation. The protocol periodically changes medium composition: introducing Notch inhibitors after 3-5 days, adjusting RA concentrations at week intervals, and removing certain modulators during maturation phases. This periodic modification of medium complexity allows efficient V2a interneuron generation while preventing cumulative toxicity and cost accumulation from continuous use of all modulators
3Reliability
If hPSCs are differentiated into V2a interneurons, then a robust source for therapy is obtained, but differentiation efficiency is low with current methods
Solution Approach 1:
The patent applies feedback by using V2a interneuron-specific markers (such as CHX10, VSX2, and LHX3 expression) to monitor differentiation progress and adjust signaling modulator concentrations accordingly. The method incorporates feedback loops where marker expression levels guide subsequent medium changes: for example, when CHX10+ cells reach a threshold level, the protocol reduces Notch inhibitor concentration or removes RA to prevent over-differentiation. This feedback control ensures high differentiation efficiency while maintaining reliable V2a interneuron quality for therapeutic applications
Solution Approach 2:
The patent implements dynamics by making the differentiation protocol adaptable and responsive to real-time cell state changes. Rather than following a rigid static protocol, the method dynamically adjusts signaling modulator concentrations based on cell response: increasing Shh activator levels if V2a commitment is insufficient, reducing RA if differentiation is too rapid, or extending Notch inhibition duration if purity is compromised. This dynamic adjustment optimizes differentiation efficiency while ensuring reliable therapeutic-grade V2a interneuron production
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach efficiently generates V2a interneurons with high expression of specific markers, enabling their functional maturation and potential use in regenerative therapies for central nervous system injuries.
Implementation Method 1
a retinoic acid signaling pathway activator
Implementation Method 2
a sonic hedgehog (Shh) signaling pathway activator
Implementation Method 3
a Notch signaling pathway inhibitor
Data Source
AI summary
Methods of generating spinal cord glutamatergic interneurons (V2a interneurons) from human pluripotent stem cells (hPSCs) are provided. A method of the present disclosure may include culturing a first population of hPSCs in vitro in a neural induction medium that includes: a retinoic acid signaling, pathway activator; a sonic hedgehog, (Shh) signaling pathway activator; and a Notch signaling pathway inhibitor, wherein the culturing results in generation of a second population of cultured cells containing CHX10+ V2a interneurons. Also provided are non-human animal models that include the hPSC-derived spinal cord glutametergic interneurons, and methods of producing the non-human animal models.